Vitrian, an end-to-end provider of investment capital and capacity-building services for biomanufacturing, has closed a $50 million investment, with the ability to scale to $65 million, into AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio, as part of a larger commitment to support biomanufacturing in Central Ohio.
 
AmplifyBio is an advanced therapy CRO and CDMO offering a full range of drug development and manufacturing services.
 
Located in the heart of Central Ohio’s advanced manufacturing corridor, adjacent to Intel’s $20 billion Ohio One semiconductor mega-fab facility and Amgen’s $360 million biomanufacturing plant, the 350,000 square-foot AMEC site is home to AmplifyBio’s multi-modality process development and quality control labs and GMP manufacturing suites.
 
“We are very excited to make our first investment in Ohio and launch a wider partnership with AmplifyBio. We have been impressed by the creativity and progressive thinking of the AmplifyBio team and look forward to further collaborations. The infrastructure investment from state and local government, favorable workforce development environment, and support of important institutional anchors in the Columbus area aligns well with our investment and partnership thesis,” said Scott Nudelman, Co-Founder and Managing Principal at Vitrian.
 
“We chose to partner with Vitrian based on the alignment of our strategic goals for our manufacturing site, and we are hopeful this is the first of many things we can do together,” said J. Kelly Ganjei, CEO of AmplifyBio. “As we execute our strategy to enable flexible advanced therapy manufacturing and ancillary services, we believe Vitrian will be a great partner.”